The short answer
No. Retatrutide is not approved by the FDA, EMA or MHRA and remains investigational everywhere. The position changed in substance during 2026: the pivotal TRIUMPH trials have now read out positively, and Eli Lilly has indicated it intends to file with the FDA in the first quarter of 2027. Filing begins a review; it is not an approval.
Key facts
- FDA status
- Not approved (investigational)
- EMA status
- Not approved
- MHRA status
- Not approved
- Trial phase
- Phase 3 complete on pivotal trials
- TRIUMPH-1 readout
- 21 May 2026: met primary endpoint
- TRIUMPH-2 / -3 readout
- July 2026: both met primary endpoints
- Stated FDA filing
- Q1 2027 (Biologics License Application)
What changed in 2026
Until May 2026 retatrutide was a compound with striking Phase 2 numbers and no pivotal data. That is no longer the case. TRIUMPH-1 reported topline results on 21 May 2026, and TRIUMPH-2 and TRIUMPH-3 followed in July, all meeting their primary endpoints. The regulatory status is unchanged (still not approved), but the reason has changed from "the evidence does not exist yet" to "the evidence exists and has not yet been submitted or reviewed".
Where does it stand in the approval process?
Lilly has stated an intention to submit a Biologics License Application to the FDA in the first quarter of 2027. Submission is the start of a formal review, which commonly runs a year or more, and regulators can request further data or decline. No MHRA or EMA filing timeline has been announced publicly, and a UK authorisation would be a separate decision from any FDA outcome.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Does the orforglipron approval affect this?
No. The MHRA authorised orforglipron (Foundayo) on 10 August 2026, but marketing authorisations are granted to a specific product for a specific indication. One incretin being licensed carries no implication for the status of a different, investigational compound from the same company.
Is it legal to buy retatrutide?
In the UK retatrutide is supplied for laboratory research only. It is not a licensed medicine, cannot be prescribed or dispensed, and is not for human use outside a registered clinical trial. That position is unaffected by the trial results above.
Frequently asked questions
When will retatrutide be approved?
No approval date exists. The stated plan is an FDA filing in Q1 2027, after which review typically takes a year or more with no guaranteed outcome.
Have the Phase 3 trials finished?
The pivotal trials have reported. TRIUMPH-1 read out in May 2026 and TRIUMPH-2 and -3 in July 2026, with further readouts including maintenance-dosing studies still expected.
Can doctors prescribe it?
No. It has no marketing authorisation in any jurisdiction.
Does a positive Phase 3 mean approval is a formality?
No. Regulators assess the full dossier including manufacturing and long-term safety, and may request additional data.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- RefTRIUMPH-1 topline results: Eli Lillyinvestor.lilly.com
- RefTwo additional Phase 3 obesity trials. Eli Lillyinvestor.lilly.com
- FDAFDA Drug Approval Searchaccessdata.fda.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedJastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More Retatrutide Research articles
- Retatrutide Molecular Structure and PropertiesA lipidated 39-mer supplied as a white lyophilised powder. What the structure implies for solubility, handling and analysis.
- What Is a Triple Agonist?One molecule activating three receptors. Why that differs from combination therapy, and what it buys and costs relative to giving three drugs.
- Retatrutide: Spellings, Codes and What Each FindsRetatrutide, LY3437943, reta. Which term finds the science, which finds the market, and the two Lilly codes easily confused with it.
- The History of RetatrutideFrom the 2022 Cell Metabolism discovery paper through Phase 2 in NEJM to the TRIUMPH Phase 3 readouts of 2026 and a signalled FDA filing.
- Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPHRetatrutide trial timeline: Phase 1 in 2020, Phase 2 in NEJM 2023, Phase 3 TRIUMPH readouts December 2025 to July 2026, FDA filing signalled for Q1 2027.